Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy
Authors
Keywords
Checkpoint inhibitor, PD-1, CTLA-4, Thrombocytopenia, Immune thrombocytopenic purpura, Melanoma
Journal
Journal for ImmunoTherapy of Cancer
Volume 5, Issue 1, Pages -
Publisher
Springer Nature
Online
2017-01-25
DOI
10.1186/s40425-017-0210-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Abnormalities of the bone marrow immune microenvironment in patients with immune thrombocytopenia
- (2016) Yang Song et al. ANNALS OF HEMATOLOGY
- Two cases of immune thrombocytopenia associated with pembrolizumab
- (2016) Audrey Le Roy et al. EUROPEAN JOURNAL OF CANCER
- Immune-related adverse events with immune checkpoint blockade: a comprehensive review
- (2016) J.M. Michot et al. EUROPEAN JOURNAL OF CANCER
- Lower expression of PD-1 and PD-L1 in peripheral blood from patients with chronic ITP
- (2016) Jun Zhong et al. Hematology
- Autoimmune hemolytic anemia induced by anti-PD-1 therapy in metastatic melanoma
- (2016) Benjamin Y. Kong et al. MELANOMA RESEARCH
- Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors
- (2016) Claire F. Friedman et al. JAMA Oncology
- Current Management of Primary Immune Thrombocytopenia
- (2015) Drew Provan et al. ADVANCES IN THERAPY
- Idiopathic thrombocytopenic purpura induced by nivolumab in a metastatic melanoma patient with elevated PD-1 expression on B cells
- (2015) S. Kanameishi et al. ANNALS OF ONCOLOGY
- PD-1 Blockers
- (2015) Jedd D. Wolchok CELL
- Treatment possibilities of ipilimumab-induced thrombocytopenia--case study and literature review
- (2015) J. Kopecky et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future
- (2015) Lieping Chen et al. JOURNAL OF CLINICAL INVESTIGATION
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Soluble Programmed Death 1 (PD-1) Is Decreased in Patients With Immune Thrombocytopenia (ITP)
- (2014) Elif Birtas Atesoglu et al. CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
- Thymic retention of CD4+CD25+FoxP3+ T regulatory cells is associated with their peripheral deficiency and thrombocytopenia in a murine model of immune thrombocytopenia
- (2012) R. Aslam et al. BLOOD
- Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
- (2012) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- The PD-1 pathway in tolerance and autoimmunity
- (2010) Loise M. Francisco et al. IMMUNOLOGICAL REVIEWS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started